MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$36,885K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Accounts receivable, prepaid exp...
Non-cash stock-based compensatio...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net income (loss)
Accounts payable, accrued expens...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-53,387
-9,491
17,527
-202,379
Depreciation and amortization
3,056
3,062
5,125
6,585
Gain on disposition of novavax cz assets
-
-
0
-
Right-of-use assets expensed, net of credits received
-
-
0
-
Non-cash stock-based compensation
8,089
7,724
7,967
8,549
Provision for excess and obsolete inventory
1,597
0
0
566
Impairment of assets held for sale
-
-
807
97,038
Impairment of long-lived assets
-
266
1,498
3,382
Loss on debt extinguishment
-
-
0
-28,714
Other items, net
-1,354
8,972
-1,303
229
Inventory
318
226
-2,148
3,753
Accounts receivable, prepaid expenses, and other assets
-8,873
-86,243
51,940
-207,927
Accounts payable, accrued expenses, and other liabilities
-37,092
-60,078
-21,543
-26,535
Deferred revenue
-4,713
-50,951
-2,367
-11,712
Net cash used in operating activities
-72,807
-32,423
-39,475
107,804
Capital expenditures, including internal-use software
588
1,270
2,076
2,017
Internal-use software
-
-
173
0
Proceeds from assets held for sale
0
39,750
19,653
-
Proceeds from disposition of novavax cz assets
-
-
0
-
Purchases of marketable securities
81,690
214,130
95,531
235,012
Proceeds from maturities of marketable securities
117,175
147,289
98,610
100,500
Net cash provided by investing activities
34,897
-28,361
20,483
-136,529
Net proceeds from sales of common stock
-
-
0
0
Proceeds on the issuance of convertible senior notes due 2031, net of issuance costs
-
-
0
42,606
Payments of costs related to issuance of 2027 convertible notes
-
-
0
-
Proceeds from the exercise of stock-based awards, net of tax withholding
-
-
-4,798
-
Proceeds from credit facility, net of issuance costs
0
46,411
-
-
Repayment of 2023 convertible notes
-
-
0
-
Net proceeds from the exercise of stock-based awards, net of tax withholding
1,727
-3,690
-
820
Finance lease payments
526
578
6,274
984
Net cash provided by (used in) financing activities
1,201
37,675
-6,604
42,442
Effect of exchange rate on cash, cash equivalents, and restricted cash
-176
-18
-1,709
658
Net decrease in cash, cash equivalents, and restricted cash
-36,885
-23,127
-27,305
14,375
Cash, cash equivalents, and restricted cash at beginning of period
232,925
256,052
283,357
545,292
Cash, cash equivalents, and restricted cash at end of period
196,040
232,925
256,052
283,357
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of marketable...
$117,175K
(-24.22%↓ Y/Y)
Net proceeds from
the exercise of...
$1,727K
(132.66%↑ Y/Y)
Net cash provided by
investing activities
$34,897K
(-7.63%↓ Y/Y)
Net cash provided by
(used in) financing...
$1,201K
(114.83%↑ Y/Y)
Canceled cashflow
$82,278K
Canceled cashflow
$526K
Net decrease in
cash, cash...
-$36,885K
(86.65%↑ Y/Y)
Canceled cashflow
$36,098K
Accounts receivable,
prepaid expenses, and...
-$8,873K
(-109.35%↓ Y/Y)
Non-cash stock-based
compensation
$8,089K
(-58.52%↓ Y/Y)
Depreciation and
amortization
$3,056K
(-80.78%↓ Y/Y)
Provision for excess and
obsolete inventory
$1,597K
(15.81%↑ Y/Y)
Other items, net
-$1,354K
(71.08%↑ Y/Y)
Purchases of marketable
securities
$81,690K
(-28.79%↓ Y/Y)
Capital expenditures,
including internal-use...
$588K
(-59.92%↓ Y/Y)
Finance lease payments
$526K
(-81.30%↓ Y/Y)
Net cash used in
operating activities
-$72,807K
(76.74%↑ Y/Y)
Canceled cashflow
$22,969K
Effect of exchange rate
on cash, cash...
-$176K
(-102.52%↓ Y/Y)
Net income (loss)
-$53,387K
(-108.54%↓ Y/Y)
Accounts payable,
accrued expenses, and...
-$37,092K
(86.49%↑ Y/Y)
Deferred revenue
-$4,713K
(99.23%↑ Y/Y)
Inventory
$318K
(-80.55%↓ Y/Y)
Buy us a coffee
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)